Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Changes in Discrete Subsets of Blood Transcriptomic and Cellular Biomarkers

Br J Dermatol. 2023 doi: 10.1093/bjd/ljad089

Prospective single-centre study of anifrolumab in refractory mucocutaneous SLE, indicates rapid efficacy of anifrolumab in discoid lupus erythematosus (DLE) and rituximab-resistant CLE.

Interferon pathway activation is highly implicated in all subtypes of CLE. While the blockade of this pathway by anifrolumab has been shown to be efficacious in SLE, the effects of this therapy on CLE of specific morphologies have not been characterised. To help address this, Carter, et al. evaluated the clinical efficacy and quality of life impact of type-I interferon-blockade in rituximab-refractory CLE, discoid and other morphologies, and transcriptomic and flow cytometric biomarkers.